标题
The high price of anticancer drugs: origins, implications, barriers, solutions
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 14, Issue 6, Pages 381-390
出版商
Springer Nature
发表日期
2017-03-14
DOI
10.1038/nrclinonc.2017.31
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States
- (2017) Qiushi Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- The Rising Price of Cancer Drugs—A New Old Problem?
- (2017) Vinay Prasad et al. JAMA Oncology
- ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe
- (2016) N. Cherny et al. ANNALS OF ONCOLOGY
- Strategies that delay or prevent the timely availability of affordable generic drugs in the United States
- (2016) G. H. Jones et al. BLOOD
- ‘Government Patent Use’: A Legal Approach To Reducing Drug Spending
- (2016) Amy Kapczynski et al. HEALTH AFFAIRS
- The High Cost of Prescription Drugs in the United States
- (2016) Aaron S. Kesselheim et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices
- (2016) Sham Mailankody et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy
- (2016) Alana Biggers et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome of second-line treatment (2L Tx) following nab-paclitaxel (nab-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC).
- (2016) David Goldstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2016) Ben Y. Durkee et al. JOURNAL OF CLINICAL ONCOLOGY
- Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia
- (2016) Aaron N. Winn et al. JOURNAL OF CLINICAL ONCOLOGY
- Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
- (2016) Scott D. Ramsey et al. JOURNAL OF CLINICAL ONCOLOGY
- Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
- (2016) Hannah Bower et al. JOURNAL OF CLINICAL ONCOLOGY
- Innovation in the pharmaceutical industry: New estimates of R&D costs
- (2016) Joseph A. DiMasi et al. JOURNAL OF HEALTH ECONOMICS
- Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
- (2016) William V. Padula et al. JNCI-Journal of the National Cancer Institute
- Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
- (2016) Sabine Vogler et al. LANCET ONCOLOGY
- The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem
- (2016) Vinay Prasad et al. MAYO CLINIC PROCEEDINGS
- Use the Bayh-Dole Act to lower drug prices for government healthcare programs
- (2016) Alfred B Engelberg et al. NATURE MEDICINE
- State Initiatives to Control Medication Costs — Can Transparency Legislation Help?
- (2016) Ameet Sarpatwari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
- (2016) H. K. Sanoff et al. ONCOLOGIST
- Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
- (2016) Andrew Hill et al. BMJ Open
- Cancer Drugs Fund requires further reform
- (2016) Richard Grieve et al. BMJ-British Medical Journal
- Cancer Drugs Fund requires further reform
- (2016) Richard Grieve et al. BMJ-British Medical Journal
- Generic Drug Approvals Since the 1984 Hatch-Waxman Act
- (2016) Ravi Gupta et al. JAMA Internal Medicine
- Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
- (2016) William V. Padula et al. JNCI-Journal of the National Cancer Institute
- The Ethical and Practical Challenges of Value-Based Cancer Care at the Patient’s Bedside
- (2016) Daniel A. Goldstein JAMA Oncology
- Perspectives on Cost and Value in Cancer Care
- (2016) Leonard B. Saltz JAMA Oncology
- An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials
- (2016) Hemanth Kumar et al. JAMA Oncology
- Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014
- (2016) Stacie B. Dusetzina JAMA Oncology
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
- (2015) N. I. Cherny et al. ANNALS OF ONCOLOGY
- How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses
- (2015) V. Prasad et al. BLOOD
- Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses
- (2015) C. J. Saret et al. BLOOD
- Are high drug prices for hematologic malignancies justified? A critical analysis
- (2015) Jagpreet Chhatwal et al. CANCER
- Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer
- (2015) Daniel A. Goldstein et al. JOURNAL OF CLINICAL ONCOLOGY
- First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis
- (2015) Daniel A. Goldstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial
- (2015) Rajendra Badwe et al. LANCET ONCOLOGY
- In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
- (2015) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- The $2.6 Billion Pill — Methodologic and Policy Considerations
- (2015) Jerry Avorn NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Five Years of Cancer Drug Approvals
- (2015) Sham Mailankody et al. JAMA Oncology
- Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice
- (2015) Aaron P. Mitchell et al. Journal of Oncology Practice
- Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in Patients
- (2014) Vinay Prasad et al. JOURNAL OF CLINICAL ONCOLOGY
- Using a Drug-Safety Tool to Prevent Competition
- (2014) Ameet Sarpatwari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Effectiveness Questions in Oncology
- (2014) Sham Mailankody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
- (2014) Tito Fojo et al. JAMA Otolaryngology-Head & Neck Surgery
- Systematic Review: Reliability of Compendia Methods for Off-Label Oncology Indications
- (2013) Amy P. Abernethy ANNALS OF INTERNAL MEDICINE
- Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer Diagnosis
- (2013) Scott Ramsey et al. HEALTH AFFAIRS
- Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
- (2013) Stacie B. Dusetzina et al. JOURNAL OF CLINICAL ONCOLOGY
- What Are The Respective Roles Of The Public And Private Sectors In Pharmaceutical Innovation?
- (2011) Bhaven N. Sampat et al. HEALTH AFFAIRS
- Projections of the Cost of Cancer Care in the United States: 2010-2020
- (2011) A. B. Mariotto et al. JNCI-Journal of the National Cancer Institute
- The Role of Public-Sector Research in the Discovery of Drugs and Vaccines
- (2011) Ashley J. Stevens et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
- (2011) Sonya Blesser Streeter et al. Journal of Oncology Practice
- Food Price and Diet and Health Outcomes
- (2010) Kiyah J. Duffey ARCHIVES OF INTERNAL MEDICINE
- New £50 million cancer fund already intellectually bankrupt
- (2010) The Lancet LANCET
- The importance of new companies for drug discovery: origins of a decade of new drugs
- (2010) Robert Kneller NATURE REVIEWS DRUG DISCOVERY
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
- (2009) T. Fojo et al. JNCI-Journal of the National Cancer Institute
- Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
- (2009) Peter B. Bach NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now